Instem plc Director Shareholding and Other Holdings (0658K)
December 23 2015 - 8:15AM
UK Regulatory
TIDMINS
RNS Number : 0658K
Instem plc
23 December 2015
Instem plc
("Instem" or the "Company")
Director Shareholding and Other Holdings in the Company
Instem (AIM: INS), a leading provider of IT solutions to the
global early development healthcare market, was notified today of
the following deals in the ordinary shares of 10 pence each in the
Company ("Ordinary Shares") by David Gare, Chairman.
David Gare is a trustee of the 'The DG 2008 Discretionary
Settlement' (the "Trust") which on 23(rd) December 2015 transferred
80,000 Ordinary Shares to each of two beneficiaries, Michael Adrian
Gare and Deborah Jane Walker, at a price of two hundred and thirty
pence per Ordinary Share (the "Transaction").
Following the Transaction, the notifiable interests of the above
parties are as follows:
Number of Ordinary Percentage of Total
Shares Held Ordinary Shares
----------------------- ------------------- --------------------
David Gare, Chairman* 2,118,427 16.2%
----------------------- ------------------- --------------------
Michael Adrian Gare 784,219 6.0%
----------------------- ------------------- --------------------
Deborah Jane Walker 784,219 6.0%
----------------------- ------------------- --------------------
*Note: these 2,118,427 Ordinary Shares are held by the
Trust.
For further information, please contact:
Instem plc +44 (0) 1785 825 600
Phil Reason, CEO
Nigel Goldsmith, CFO
N+1 Singer (Nominated Adviser
& Broker) +44 (0) 20 7496 3000
Richard Lindley
Walbrook Financial PR +44 (0) 20 7933 8780
Paul Cornelius instem@walbrookpr.com
Helen Cresswell
Sam Allen
About Instem plc
Instem is a leading supplier of IT applications to the early
development healthcare market, delivering compelling solutions for
data collection, management and analysis across the R&D
continuum. Instem applications are in use by customers worldwide,
meeting the rapidly expanding needs of life science and healthcare
organisations for data-driven decision making leading to safer,
more effective products.
Instem's portfolio of software solutions increases client
productivity by automating study-related processes while offering
the unique ability to generate new knowledge through the extraction
and harmonisation of actionable scientific information.
Instem supports over 400 clients through full service offices in
the United States, the United Kingdom, India and China, with
additional presence in France and Japan.
To learn more about Instem solutions and its mission, please
visit www.instem.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSTJBJTMBBTBIA
(END) Dow Jones Newswires
December 23, 2015 08:15 ET (13:15 GMT)
Instem (LSE:INS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Instem (LSE:INS)
Historical Stock Chart
From Jul 2023 to Jul 2024